LOGIN  |  REGISTER
Assertio
Viking Therapeutics

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

July 02, 2025 | Last Trade: US$66.73 0.10 0.15

MARLBOROUGH, Mass. / Jul 02, 2025 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (313) 209-4906 (for international callers) and referencing access code 5212316. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins.

Hologic will provide a live and webcast replay of the call on the Company’s website at investors.hologic.com. The call will be available there for 30 days. The webcast replay will be available approximately two hours after the call ends.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page